medigraphic.com
ISSN 1561-302X (Print)

2014, Number 2

<< Back Next >>

Rev cubana med 2014; 53 (2)

Autoantibodies as biomarkers of disease activity in systemic lupus erythematosus

Kokuina E

Language: Spanish
References: 93
Page: 201-223
PDF size: 155.46 Kb.


ABSTRACT

There is an urgent need for biomarkers to identify and predict activity phases of systemic lupus erythematosus (SLE) to optimize the patients clinical management. Out of hundreds of autoantibodies present in SLE patients, very few are candidates for biomarkers of clinical disease activity and none has been established as an independent criterion for clinical decision making. Identifying relapse of SLE is more art than science. It has recently been suggested that the positive correlation between autoantibody levels and SLE activity may be subverted by the presence of protective autoantibodies opposed to tissue damage produced by pathogenic autoantibodies. The anti-nucleosome, anti-dsDNA and anti-C1q antibodies are associated with disease activity assessed by several international rating systems such as the SLEDAI, BILAG ECLAM and, partly in cross-sectional studies. These biomarkers are promising for clinical monitoring of SLE patients, but they still need the validation of multi-scale controlled studies. This review was to summarize the challenges of discovery and validation of biomarkers of autoantibodies in SLE activity within the functional complexity of the autoantibodies.


REFERENCES

  1. Lopez R, Davidson JE, Beeby MD, Egger PJ, Isenberg DA. Lupus disease activity and the risk of subsequent organ damage and mortality in a large lupus cohort. Rheumatology. 2012;51:491-8.

  2. Jung JY, Bae CB, Suh CH. Promising biomarkers for systemic lupus erythematosus. Expert Opin Med Diagn. 2013;7:601-13.

  3. Romero-Diaz J, Isenberg D, Ramsey-Goldman R. Measures of adult systemic lupus erythematosus: updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus ActivityMeasure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care Res. 2011;63(Suppl 11):S37-46.

  4. Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum. 2009;61:1143-51.

  5. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. II. Markers of disease activity. Arthritis Rheum. 2004;50:2048-65.

  6. Liang MH, Simard JF, Costenbader K, Dore BT, Ward M, Fortin PR, et al. Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus. Endocr Metab Immune Disord Drug Targets. 2009;9:108-12.

  7. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34:501-37.

  8. Bruner BF, Guthridge JM, Lu R, Vidal G, Kelly JA, Robertson JM, et al. Comparison of autoantibody specificities between traditional and bead-based assays in a large, diverse collection of patients with systemic lupus erythematosus and family members. Arthritis Rheum. 2012;64:3677-86.

  9. Kavanaugh AF, Tomar R, Reveille J, Solomon DH, Homburger HA. Guidelines for clinical use of the antinuclear antibody test and tests for specific autoantibodies to nuclear antigens. American College of Pathologists. Arch Pathol Lab Med. 2000;124:71-81.

  10. Olsen NJ, Li Q-Z, Quan J, Wang L, Mutwally A, Karp DR. Autoantibody profiling to follow evolution of lupus syndromes. Arthritis Res Ther. 2012;14:R174.

  11. Rekvig OP, Putterman C, Casu C, Gao HX, Ghirardello A, Mortensen ES, et al. Autoantibodies in lupus: Culprits or passive bystanders? Autoimmun Rev. 2012;11:596-603.

  12. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25:1271-7.

  13. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677-86.

  14. McCarty GA, Rice JR, Bembe ML, Pisetsky DS. Independen expression of autoantibodies in systemic lupus erythematosus. J Rheumatol. 1982;9:691-5.

  15. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-ADN antibodies against necrotic nucleosomes. J Am Soc Nephrol. 2009;20:696-704.

  16. Akhter E, Burlingame R, Seaman A, Magder L, Petri M. Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2011;20:1267-74.

  17. Moroni G, Radice A, Giammarresi G, Quaglini S, Gallelli B, Leoni A, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis. 2009;68:234-7.

  18. Yin Y, Wu X, Shan G, Zhang X. Diagnostic value of serum anti-C1q antibodies in patients with lupus nephritis: a meta-analysis. Lupus. 2012;21:1088-97.

  19. Buneva VN, Krasnorutskii MA, Nevinsky GA. Natural antibodies to nucleic acids. Biochemistry (Mosc.). 2013;78:127-43.

  20. Shoenfeld Y, Toubi E. Protective autoantibodies: Role in homeostasis, clinical importance, and therapeutic potential. Arthritis Rheum. 2005;52:2599-606.

  21. Abdulahad DA, Westra J, Blizet J, Limburg PC, Kallenberg CG, Bijl M. High mobility group box 1 (HMGB1) and anti-HMGB1antibodies and their relation to disease characteristics in systemic lupus erythematosus. Arthritis Res Ther. 2011;13:R71.

  22. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. J Immunol. 2011;187:2626-31.

  23. Mahendra A, Sharma M, Rao DN, Peyron I, Planchais C, Dimitrov JD, et al. Antibody-mediated catalysis: induction and therapeutic relevance. Autoimmun Rev. 2013;12:648-52.

  24. Furtado J, Isenberg DA. B cell elimination in systemic lupus erythematosus. Clin Immunol. 2013;146:90-103.

  25. Doolittle WF. Is junk DNA bunk? A critique of ENCODE. Proc Natl Acad Sci USA. 2013;110:5294-300.

  26. Pisetsky DS. Antinuclear antibodies in rheumatic disease: a proposal for a function-based classification. Scand J Immunol. 2012;76:223-8.

  27. Dragon-Durey MA, Blanc C, Marinozzi MC, van Schaarenburg RA, Trouw LA. Autoantibodies against complement components and functional consequences. Mol Immunol. 2013;56:213-21.

  28. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33.

  29. Dorner T, Heimbacher C, Farner NL, Lipsky PE. Enhanced mutational activity of Vkappa gene rearrangements in systemic lupus erythematosus. Clin Immunol. 1999;92:188-96.

  30. Emlen W, O'Neill L. Clinical significance of antinuclear antibodies: comparison of detection with immunofluorescence and enzyme-linked immunosorbent assays. Arthritis Rheum. 1997;40:1612-8.

  31. Aviña-Zubieta JA, Galindo-Rodriguez G, Kwan-Yeung L, Davis P, Russell AS. Clinical evaluation of various selected ELISA kits for the detection of anti-DNA antibodies. Lupus. 1995;4:370-4.

  32. Sabbaga J, Pankewycz OG, Lufft V, Schwartz RS, Madaio MP. Cross-reactivity distinguishes serum and nephritogenic anti-DNA antibodies in human lupus from their natural counterparts in normal serum. J Autoimmun. 1990;3:215-35.

  33. Reveille JD. Predictive value of autoantibodies for activity of systemic lupus erythematosus. Lupus. 2004;13:290-7.

  34. Smeenk R, Brinkman K, van den Brink H, Swaak T. Antibodies to DNA in patients with systemic lupus erythematosus. Their role in the diagnosis, the followup and the pathogenesis of the disease. Clin Rheumatol. 1990;9(Suppl 1):100-10.

  35. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-strandedDNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus: a long-term, prospective study. Arthritis Rheum. 1990;33:634-43.

  36. Ravirajan CT, Rowse L, MacGowan JR, Isenberg DA. An analysis of clinical disease activity and nephritis-associated serum autoantibody profiles in patients with systemic lupus erythematosus: a cross-sectional study. Rheumatology [Oxford]. 2001;40:1405-12.

  37. Gladman DD, Hirani N, Ibanez D, Urowitz MB. Clinically active serologically quiescent systemic lupus erythematosus. J Rheumatol. 2003;30:1960-2.

  38. Matrat A, Veysseyre-Balter C, Trolliet P, Villar E, Dijoud F, J Bienvenu J, et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus. 2011;20:28-34.

  39. Andrejevic S, Jeremic I, Sefik-Bukilica M, Nikolic M, Stojimirovic B, Bonaci- Nikolic B. Immunoserological parameters in SLE: high-avidity anti-dsDNA detected by ELISA are the most closely associated with the disease activity Clin Rheumatol. 2013;32:1619-26.

  40. van den Berg L, Nossent H, Rekvig O. Prior anti-dsDNA antibody status does not predict later disease manifestations in systemic lupus erythematosus. Clin Rheumatol. 2006;25:347-52.

  41. Egner W. The use of laboratory tests in the diagnosis of SLE. J Clin Pathol. 2000;53:424-32.

  42. Villalta D, Bizzaro N, Bassi N, Zen M, Gatto M, Ghirardello A, et al. Anti-dsDNA antibody isotypes in systemic lupus erythematosus: IgA in addition to IgG antidsDNA help to identify glomerulonephritis and active disease. PLoS ONE. 2013;8(8):e71458. doi:10.1371/journal.pone.0071458.

  43. Izui S, Lambert PH, Miescher PA. In vitro demonstration of a particular affinity of glomerular basement membrane and collagen for DNA: a possible basis for a local formation of DNA-anti-DNA complexes in systemic lupus erythematosus. J Exp Med. 1976;144:428-43.

  44. D'Andrea DM, Coupaye Gerard B, Kleyman TR, Foster MH, Madaio MP. Lupus autoantibodies interact directly with distinct glomerular and vascular cell surface antigens. Kidney Int. 1996;49:1214-21.

  45. Winfield JB, Faiferman I, Koffler D. Avidity of anti-DNA antibodies in serum and IgG glomerular eluates from patients with systemic lupus erythematosus: association of high avidity antinative DNA antibody with glomerulonephritis. J Clin Invest. 1977;59:90-6.

  46. Izui S, Lambert PH, Miescher PA. Failure to detect circulating DNA-anti-DNA complexes by four radioimmunological methods in patients with systemic lupus erythematosus. Clin Exp Immunol. 1977;30:384-92.

  47. van der Vlag J, Berden JH. Lupus nephritis: role of antinucleosome autoantibodies. Semin Nephrol. 2011;31:376-89.

  48. Muñoz LE, Lauber K, Schiller M, Manfredi AA, Herrmann M. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol. 2010;6:280-9.

  49. Sato N, Ohsawa I, Nagamachi S, Ishii M, Kusaba G, Inoshita H, et al. Significance of glomerular activation of the alternative pathway and lectin pathway in lupus nephritis. Lupus. 2011;20:1378-86.

  50. Doria A, Gatto M. Nephritogenic-antinephritogenic antibody network in lupus glomerulonephritis. Lupus. 2012;21:1492-6.

  51. Bassi N, Ghirardello A, Blank M, Zampieri S, Sarzi-Puttini P, Mantovani A, et al. IgG anti-pentraxin 3 antibodies in systemic lupus erythematosus. Ann Rheum Dis. 2010;69:1704-10.

  52. Witte T. IgM antibodies against dsDNA in SLE. Clin Rev Allerg Immunol. 2008;34:345-7.

  53. Yung S, Chan TM. Autoantibodies and Resident Renal Cells in the Pathogenesisof Lupus Nephritis: Getting to Know the Unknown. Clin Dev Immunol. 2012;2012:139365. doi:10.1155/2012/139365

  54. Yung S, Cheung KF, Zhang Q, Chan TM. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol. 2010;21:1912-27.

  55. Nezlin R, Alarcon-Segovia D, Shoenfeld Y. Immunochemical determination in immune complexes present in the circulation of patients with systemic lupus erythematosus. J Autoimmun. 1998;11:489-93.

  56. Gómez-Puerta JA, Burlingame RW, Cervera R. Antichromatin (anti-nucleosome) antibodies: diagnostic and clinical value. Autoimmun Rev. 2008;7:606-11.

  57. Burlingame RW. The clinical utility of antihistone antibodies. Autoantibodies reactive with chromatin in systemic lupus erythematosus and drug induced lupus. Clin Lab Med. 1997;17:367-76.

  58. Gómez-Puerta JA, Molina JF, Anaya JM, Molina J. Clinical significance of antichromatin antibodies in systemic lupus erythematosus. Lupus. 2001;10(Supp 1):S73.

  59. Amoura Z, Koutouzov S, Chabre H, Cacoub P, Amoura I, Musset L, et al. Presence of antinucleosome autoantibodies in a restricted set of connective tissue diseases. Antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum. 2000;43:76-84.

  60. Cervera R, Viñas O, Ramos-Casals M, Font J, Garcia-Carrasco M, Siso A, et al. Antichromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis. 2003;62:431-4.

  61. Schett G, Smolen J, Zimmermann C, Hiesberger H, Hoefler E, Fournel S, et al. The autoimmune response to chromatin antigens in systemic lupus erythematosus: autoantibodies against histone H1 are highly specific markers for SLE associated with increased disease activity. Lupus. 2002;11:704-15.

  62. Cairns PA, McMillan SA, Crockard AD, Meenagh GK, Duffy EM, Armstrong DJ, et al. Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis. 2003;62:272-3.

  63. Min DJ, Kim SJ, Park SH, Seo YI, Kang HJ, Kim WU, et al. Anti-nucleosome antibody: significance in lupus patients lacking anti-double-stranded DNA antibody. Clin Exp Rheumatol. 2002;20:13-8.

  64. Ghirardello A, Doria A, Zampieri S, Tarricone E, Tozzoli R, Villalta D, et al. Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun. 2004;22:235-40.

  65. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J. Antinucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatology. 2004;43:220-4.

  66. Braun A, Sis J, Max R, Mueller K, Fiehn C, Zeier M, et al. Anti-chromatin and anti-C1q antibodies in systemic lupus erythematosus compared to other systemic autoimmune diseases. Scand J Rheumatol. 2007;36:291-8.

  67. Tikly M, Gould T, Wadee AA, van der Westhuizen E, Mokgethwa BB. Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol. 2007;26:2121-5.

  68. Su Y, Jia RL, Han L, Li ZG. Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol. 2007;122:115-20.

  69. Campos LMA, Kiss MHB, Scheinberg MA, Mangueira CLP, Silva CA. Antinucleosome antibodies in patients with juvenile systemic lupus erythematosus. Lupus. 2006;15:496-500.

  70. Suleiman S, Kamaliah D, Nadeem A, Naing NN, Che Maraina CH. Antinucleosome antibodies as a disease activity marker in patients with systemic lupus erythematosus. Intern J Rheum Dis. 2009;12:100-6.

  71. Quattrocchi P, Barrile A, Bonanno D, Giannetto L, Patafi M, Tigano V, et al. The role of anti-nucleosome antibodies in systemic lupus erythematosus. Results of a study of patients with systemic lupus erythematosus and other connective tissue diseases. Reumatismo. 2005;57:109-13.

  72. Souza A, da Silva LM, Oliveira FR, Roselino AMF, Louzada-Junior P. Antinucleosome and anti-chromatin antibodies are present in active systemic lupus erythematosus but not in the cutaneous form of the disease. Lupus. 2009;18:223- 9.

  73. Gutiérrez-Adrianzén OA, Koutouzov S, Mota RM, das Chagas Medeiros MM, Bach JF, de Holanda Campos H. Diagnostic value of anti-nucleosome antibodies in the assessment of disease activity of systemic lupus erythematosus: a prospective study comparing anti-nucleosome with anti-dsDNA antibodies. J Rheumatol. 2006;33:1538-44.

  74. Grootscholten C, Dieker JW, McGrath FD, Roos A, Derksen RH, van der Vlag J, et al. A prospective study of anti-chromatin and anti-C1q autoantibodies in patients with proliferative lupus nephritis treated with cyclophosphamide pulses or azathioprine/methylprednisolone. Ann Rheum Dis. 2007;66:693-6.

  75. Ng KP, Masson JJ, Rahman A, Isenberg DA. Association of antinucleosome antibodies with disease flare in serologically active clinically quiescent patients with systemic lupus erythematosus. Arthritis Rheum. 2006;55:900-4.

  76. Kim HA, Jeon JY, Choi GS, Sung JM, Kim MJ, Yun JM, et al. The antichromatin antibodies can be useful as a diagnostic tool and disease activity marker of systemic lupus erythematosus in Koreans. Clin Immunol. 2008;128:277-83.

  77. Biesen R, Dähnrich C, Rosemann A, Barkhudarova F, Rose T, Jakob O, et al. Anti-dsDNA-NcX ELISA: dsDNA-loaded nucleosomes improve diagnosis and monitoring of disease activity in systemic lupus erythematosus. Arthr Res Ther. 2011;13: R26.

  78. Masood S, Jayne D, Karim Y. Beyond immunosuppression - challenges in the clinical management of lupus nephritis. Lupus. 2009;18:106-15.

  79. O'Flynn J, Flierman R, van der Pol P, Rops A, Satchell SC, Mathieson PW, et al. Nucleosomes and C1q bound to glomerular endothelial cells serve as targets for autoantibodies and determine complement activation. Mol Immunol. 2011;49:75-83.

  80. Kiss E, Lakos G, Szegedi G, Poor G, Szodoray P. Anti-nucleosome antibody, a reliable indicator for lupus nephritis. Autoimmunity. 2009;42:393-8.

  81. Manson JJ, Ma A, Rogers P, Mason LJ, Berden JH, van der Vlag, Jet al. Relationship between anti-dsDNA, anti-nucleosome and anti-alpha-actinin antibodies and markers of renal disease in patients with lupus nephritis: a prospective longitudinal study. Arthritis Res Ther. 2009;11:R154.

  82. Mok CC, Ho LY, LeungHW, Wong LG. Performance of anti-C1q, antinucleosome and anti-dsDNA antibodies for detecting concurrent disease activity of systemic lupus erythematosus. Trans Res. 2010;156:320-5.

  83. Hung WT, Chen YM, Lan JL, Chen HH, Chen YH, Chen DY, et al. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis. Lupus. 2011;20:1404-10.

  84. Bigler C, Lopez-Trascasa M, Potlukova E, Moll S, Danner D, Schaller M, et al. Antinucleosome antibodies as a marker of active proliferative lupus nephritis. Am J Kidney Dis. 2008;51:624-9.

  85. Yoshimi R, Ueda A, Ozato K, Ishigatsubo Y. Clinical and pathological roles of Ro/SSA autoantibody system. Clin Dev Immunol. 2012;2012:606195. doi:10.1155/2012/606195

  86. Xue D, Shi H, Smith JD, Chen X, Noe DA, Cedervall T, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci USA. 2003;100:7503-8.

  87. Migliorini P, Baldini C, Rocchi V, Bombardieri S. Anti-Sm and anti-RNP antibodies. Autoimmunity. 2005;38:47-54.

  88. Agarwal S, Harper J, Kiely PDW. Concentration of antibodies to extractable nuclear antigens and disease activity in systemic lupus erythematosus. Lupus. 2009;18:407-12.

  89. Kurien BT, Scofield RH. Autoantibody Determination in the Diagnosis of Systemic Lupus Erythematosus. Scand J Immunol. 2006;64:227-35.

  90. Kvarnstrom M, Dzikaite-Ottosson V, Ottosson L, Gustafsson JT, Gunnarsson I, Svenungsson E et al. Autoantibodies to the functionally active RING-domain of Ro52/SSA are associated with disease activity in patients with lupus. Lupus. 2013;22:477-85.

  91. Martinez-Cordero E, Martinez-Miranda E, Negrete-Garcia MC, Padilla A, Aguilar Leon DE. Anti-dsDNA and Sm autoantibodies in systemic lupus erythematosus. Clin Rheumatol. 1992;11:341-5.

  92. Gussin HA, Ignat GP, Varga J, Teodorescu M. Anti-topoisomerase I (anti-Scl-70) antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:376-83.

  93. Liu CC, Kao AH, Manzi S, Ahearn JM. Biomarkers in systemic lupus erythematosus: challenges and prospects for the future. Ther Adv Musculoskel Dis. 2013;5:210-33.




2020     |     www.medigraphic.com